文献速递介入腹部胸部CT

CT透视引导活检中机器人穿刺针置入:前瞻性首次人体可行性试验

Robotic needle insertion during computed tomography fluoroscopy-guided biopsy: prospective first-in-human feasibility trial.
PubMed 文献 · Eur Radiol · 2019-08-23

这项前瞻性首次人体试验评估了在CT透视引导活检中使用机器人置入活检引导针的可行性与安全性,纳入10例患者,病灶位于肾、肺、纵隔、肾上腺和肌肉。所有患者机器人置入均可行并获病理诊断,无机器相关故障,8例患者共发生11起不良事件(10起I级,1起IIIa级)。

要点

  • 机器人置入活检引导针在肾、肺、纵隔、肾上腺和肌肉病灶均可行
  • 可行性定义为置入后针尖距最近病灶边缘≤10 mm,所有患者均达到
  • 无机器相关故障,8例患者发生11起不良事件,其中10起I级、1起IIIa级

核心结论

  • 使用本研究的机器人在CT透视引导活检中置入活检引导针在人体多个部位可行,并均获得病理诊断。

研究设计与样本

  • 前瞻性首次人体试验,纳入10例患者(4例女性、6例男性,平均年龄72岁,范围52-87岁),病灶平均最大径28 mm(范围14-52 mm),位于肾(4例)、肺(3例)、纵隔(1例)、肾上腺(1例)和肌肉(1例);纳入标准为四肢或躯干病灶≥10 mm且需CT透视引导活检病理诊断,排除高危结构距计划针道10 mm以内者;机器人置入活检引导针后手动使用活检针获取标本,随访14天。

关键影像表现/征象

  • 所有患者机器人置入活检引导针均可行,并均获得病理诊断
  • 无机器相关故障发生
  • 8例患者共发生11起不良事件,包括10起Clavien-Dindo I级事件和1起IIIa级事件

诊断标准与关键数值

  • 可行性定义为CT透视图像上置入后针尖与最近病灶边缘距离≤10 mm,所有患者均满足

临床应用与阅片要点

  • 作者认为在CT透视引导活检中,使用该机器人置入活检引导针在人体多个部位可行

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: This was a prospective, first-in-human trial to evaluate the feasibility and safety of insertion of biopsy introducer needles with our robot during CT fluoroscopy-guided biopsy in humans.

MATERIALS AND METHODS: Eligible patients were adults with a lesion ≥ 10 mm in an extremity or the trunk requiring pathological diagnosis with CT fluoroscopy-guided biopsy. Patients in whom at-risk structures were located within 10 mm of the scheduled needle tract were excluded. Ten patients (4 females and 6 males; mean [range] age, 72 [52-87] years) with lesions (mean [range] maximum diameter, 28 [14-52] mm) in the kidney (n = 4), lung (n = 3), mediastinum (n = 1), adrenal gland (n = 1), and muscle (n = 1) were enrolled. The biopsy procedure involved robotic insertion of a biopsy introducer needle followed by manual acquisition of specimens using a biopsy needle. The patients were followed up for 14 days. Feasibility was defined as the distance of ≤ 10 mm between needle tip after insertion and the nearest lesion edge on the CT fluoroscopic images. The safety of robotic insertion was evaluated on the basis of machine-related troubles and adverse events according to the Clavien-Dindo classification.

RESULTS: Robotic insertion of the introducer needle was feasible in all patients, enabling pathological diagnosis. There was no machine-related trouble. A total of 11 adverse events occurred in 8 patients, including 10 grade I events and 1 grade IIIa event.

CONCLUSION: Insertion of biopsy introducer needles with our robot was feasible at several locations in the human body.

KEY POINTS: • Insertion of biopsy introducer needles with our robot during CT fluoroscopy-guided biopsy was feasible at several locations in the human body.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Hiraki T, Kamegawa T, Matsuno T, et al. Robotic needle insertion during computed tomography fluoroscopy-guided biopsy: prospective first-in-human feasibility trial. Eur Radiol. 2019. PMID: 31444597. doi:10.1007/s00330-019-06409-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。